ANG Lifesciences Share Price Today | Stock Price & ANG Lifesciences Share Screener
As of October 5, 2026, the live ANG Lifesciences share price (BSE: ANG) is ₹39.38, down 1.99% from the previous close, with shares trading between ₹39.38 and ₹39.50 in today's trading session, and a 52-week range of ₹18.42–₹42.83. Check ANG price range for the annual price range and momentum. Use the ANG Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today ANG Lifesciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹24 and net income of ₹-1, with EBITDA of ₹3, an operating margin of 11.0% and a profit margin of -4.2%.
ANG Lifesciences Share Price Chart
Track the current stock price of ANG Lifesciences with an interactive chart. Analyse ANG share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete ANG Lifesciences stock quote in one place.
The quote of ₹39.38 sits between the 52-week low of ₹18.42 and the 52-week high of ₹42.83, and the latest session moved -1.99% from the previous close.
ANG Lifesciences Company Profile - Fundamental Screener
Screen ANG Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ANG shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE236W01016.
Company Details
Classification
Identifiers and Leadership
ANG Lifesciences Balance Sheet Screener
Screen ANG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹209, down from ₹230 in 2025.
Latest statistics put total assets at ₹209 and shareholder funds at ₹53, with a leverage ratio of 1.11.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
Assets |
|||||
| Total Assets | 209 | 230 | 242 | 278 | 291 |
| Current Assets | 145 | 161 | 173 | 183 | 193 |
| Fixed Assets | 51 | 57 | 58 | 88 | 93 |
Liabilities |
|||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7 | 22 | 22 | 29 | 41 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||
| Total Equity | 53 | 64 | 76 | 86 | 84 |
| Share Capital | 13 | 13 | 13 | 13 | 10 |
| Reserves & Surplus | 40 | 46 | 59 | 69 | 69 |
ANG Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen ANG Lifesciences income statement and profit fundamentals. Analyze ANG quarterly results. ANG Lifesciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹24 and net profit was ₹-1, equal to earnings per unit of ₹-1.07, at an operating margin of 11%.
In that period expenses were ₹21, interest cost ₹2 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹15 and net profit of ₹-4.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 24 | 15 | 18 | 25 | 26 | 19 | 38 | 20 | 33 | 25 | 49 | 57 | 34 | 19 | 96 |
| Expenses | 21 | 17 | 18 | 24 | 26 | 21 | 36 | 20 | 31 | 27 | 50 | 50 | 32 | 21 | 83 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 3 | -2 | 0 | 1 | 0 | -3 | 2 | 0 | 3 | -2 | -1 | 7 | 2 | -2 | 13 |
| Operating Profit % | 11.00% | -13.00% | -4.00% | 3.00% | 0.00% | -14.00% | 4.00% | -9.00% | 7.00% | -9.00% | -26.00% | 12.00% | 5.00% | -10.00% | 13.00% |
| Depreciation | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | -1 | -6 | -4 | -3 | -3 | -6 | -4 | -4 | -1 | -6 | -6 | 2 | -3 | -6 | 7 |
| Tax | 0 | -1 | -2 | -1 | 0 | -1 | 0 | -1 | 1 | -1 | -1 | 1 | 0 | 0 | 2 |
| Net Profit | -1 | -4 | -2 | -2 | -3 | -5 | -4 | -3 | -2 | -5 | -5 | 2 | -2 | -6 | 5 |
| EPS | -1.07 | -3.24 | -1.56 | -1.52 | -2.24 | -3.60 | -2.75 | -2.35 | -1.53 | -3.98 | -3.63 | 1.41 | -1.74 | -4.52 | 5.16 |
ANG Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen ANG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹0.
Over the same period, investing activities used ₹2 and financing activities provided ₹2.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
Cash from Operations and Investing | ||||
| Operating Activities | 0 | -10 | 26 | 25 |
| Investing Activities | -2 | 20 | -9 | -44 |
Financing and Net Cash | ||||
| Financing Activities | 2 | -10 | -17 | 20 |
| Net Cash Flow | 0 | 0 | 0 | 0 |
ANG Lifesciences Shareholding Pattern Screener
See ANG Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check ANG Lifesciences promoter holding and ownership changes for ANG on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 70.60%, foreign institutions 0.00%, domestic institutions 0.00% and the public 26.30%, spread across 5,946 shareholders.
The shareholder count was 5,946 in 2026-Jun, compared with 5,952 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 26.30% | 26.21% | 26.26% | 26.18% | 26.11% | 26.11% | 25.92% | 25.45% |
| Other Holding | 3.10% | 3.19% | 3.13% | 3.21% | 3.29% | 3.29% | 3.48% | 3.95% |
| Shareholder Count | 5,946 | 5,952 | 6,084 | 6,273 | 6,400 | 6,508 | 6,517 | 6,468 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by ANG Lifesciences. ANG Lifesciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹1.00 | 1.33% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
ANG Lifesciences Stock Index Membership - Nifty & Sensex
See which indices include ANG Lifesciences stock. Check ANG index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
ANG Lifesciences Market Events Screener - Corporate Actions
Get ANG Lifesciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check ANG Lifesciences stock events that may affect ANG share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | 20.48% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | -2.33% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -5.73% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | 3.50% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -2.04% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -1.68% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -3.93% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -5.27% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -5.83% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.04% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -8.62% |
| 2022-07-13 | 2022-07-14 | Bonus | 1:4 | 36.04% |
| 2021-11-02 | 2021-11-04 | Dividend | ₹ 1.00 /share | 47.69% |
| 2021-09-22 | Bonus | 1:1 | - |
ANG Lifesciences Competitors Screener - Peer Stocks Comparison
Screen ANG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 40.74 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 63.87 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 46.50 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 66.57 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 45.42 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 64.04 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 55.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 63.11 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.66 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 35.30 |
ANG Lifesciences Company Announcements - News & Reports Screener
Screen ANG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 30, 2026.
The next most recent announcements are dated September 7, 2026 and September 7, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-07 | Reg. 34 (1) Annual Report. | - |
| 2026-09-07 | Notice Of 20Th AGM Of The Company On Wednesday 30Th September 2026 At 12 :00 Noon. (IST) Through Video Conferencing (VC) / Other Audio Visual Means (OA VM). | - |
| 2026-09-07 | Intimation Of Book Closure | - |
| 2026-09-07 | Intimation Of 20Th Annual General Meeting | - |
| 2026-09-07 | Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For Intimation Of AGM | - |
| 2026-08-14 | Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations 2015 | - |
| 2026-08-14 | Board Meeting Outcome for Board Meeting Outcome For Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations 2015 | - |
| 2026-08-07 | Board Meeting Intimation for Consideration And Approval Of Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2026. | - |
| 2026-07-21 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-19 | Closure of Trading Window | - |
| 2026-06-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Results - 31.03.2026 | - |
| 2026-05-30 | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-22 | Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-04-17 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-10 | Clarification On Price Movement In Shares | - |
| 2026-04-10 | Clarification sought from ANG Lifesciences India Ltd | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹39.38, within a 52-week range of ₹18.42 to ₹42.83. The P/E ratio is -4.03 and the P/B ratio is 1.01, with earnings per unit of ₹-8.43. Market capitalisation stands at ₹52.53 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 5 balance sheet periods, 15 income statement periods, 4 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.